2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Treatment Considerations, Drug Development, Biological Therapies, Transplantation, Non-Biological Therapies, Pharmacology, Biological Processes, Pathogenesis, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Bleeding and Clotting, Hemophilia, Platelet Disorders, Thrombotic Disorders, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Study Population, Human, Adult, Animal Model
PAPER

4755 Differences in the platelet lipidome across development

Kimberley Banfield, MBBS, Rolf Dale Bates2, Nicholas Giroux3, Erin Soule-Albridge4, Amalia El Nems5, Jesselin Romero Escobar6, Martha Sola-Visner, MD7, Christopher Thom, MD, PhD8, Patricia Davenport, MD9
1 Boston Children's Hospital, Boston, Massachusetts, United States
2 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
3 Boston Children's Hospital, Boston, Massachusetts, United States
4 Boston Children's Hospital, Boston, Massachusetts, United States
5 Boston Children's Hospital, Boston, Massachusetts, United States
6 Boston Children's Hospital, Boston, Massachusetts, United States
7 Boston Children's Hospital, Boston, Massachusetts, United States
8 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
9 Boston Children's Hospital, Boston, Massachusetts, United States

Introduction: Thrombocytopenia is common in the neonatal population and historically, preterm infants have received prophylactic platelet (PLT) transfusions at higher PLT count thresholds than used in children/adults in an effort to reduce their baseline bleeding risk. However, in 2019 the PlaNeT-2 Trial found an increased incidence of major bleeding and/or death in neonates randomized to receive a transfusion at a higher vs. a lower PLT count threshold. Investigation into the mechanisms underlying these adverse outcomes suggest that they are related to the developmental mismatch that occurs when neonates receive a transfusion of relatively hyper-active adult PLTs. Recently, we characterized the PLT proteome across development and found that adult PLTs are enriched in immunomodulatory proteins, whereas neonatal PLTs are enriched in proteins involved in metabolic processes, particularly lipid metabolism (Thom, Davenport et al., JTH 2024). PLTs contain both structural lipids and bioactive lipid mediators that regulate cellular signaling. Thus, we hypothesized that developmental differences in PLT lipid composition could contribute to the functional differences in activation between adult and neonatal PLTs.

 

Methods: To test this hypothesis, we collected 11 cord blood samples from full-term cesarean sections and 13 adult blood samples from healthy volunteers. PLTs were washed using the PLT rich plasma method, pelleted, and flash frozen prior to mass spectrometry-based lipidomic and oxylipin analyses. Final PLT counts were measured using a Sysmex Hematology Analyzer (XNV-1000) and PLT activation status (CD62P MFI) and purity (%CD41+) were measured by flow cytometry. Datasets were normalized to internal standards and per-sample platelet count prior to statistical analysis.

 

Results: Cord blood donors were 36% female with an average gestational age of 38 weeks and 4 days; PLTs from cord blood had an average CD62P MFI of 432 (range 66.8 – 2837) and average CD41+ purity of 97.3% (range 92.2 – 99.7%). Adult blood donors were 54% female with an average age of 38.4 years (range 20 – 68 years); PLTs from adult blood had an average CD62P MFI of 315.4 (range 51.4 – 2500) and an average CD41+ purity of 99.3% (range 98.4 – 99.4%). After adjusting for sex, PLT purity, P-selectin MFI, and PLT count, we identified 491 lipid species with differential abundance (FDR≤0.05), of which 181 unique lipids were measured at higher abundances in neonatal PLTs and 310 at higher abundances in adult PLTs. We observed clear separation between the neonatal and adult PLT samples using principal component analysis. Principal component 1 explained 58.4% of the variation in lipid abundance and was correlated with development (i.e., neonatal vs. adult; Pearson R2=0.86, p<0.0001). We observed differential abundance of lipid species from all major classes, including phosphatidylethanolamines, phosphatidylserines (PS), sphingolipids, and phosphatidylglycerol—lipid classes primarily associated with membrane composition and cellular metabolism. Adult PLTs had higher abundance of oxylipins (e.g., 7-fold enrichment of the linoleate/linolenate family) and specific diacylglycerol species (e.g., 3.5-fold enrichment of 7 saturated species). Such lipid classes are involved in the regulation of PLT activation, inflammatory signaling, and lipid mediator production. As for membrane-associated lipid species, neonatal PLTs contain significantly more ceramide, which has been associated with membrane PS exposure and a procoagulant or apoptotic phenotype. In contrast, adult PLTs contain more sphingomyelin, which sits in the outer membrane leaflet and influences receptor clustering and signaling through modifying raft organization. Sphingomyelin and ceramide are biologically linked: sphingomyelin can be hydrolyzed into ceramide, and ceramide can be converted back into sphingomyelin in the Golgi. Thus, the ratio of ceramide:sphingomyelin (Cer:SM) is an important biomarker for membrane fluidity. Indeed, the Cer:SM ratio was 1.4-fold higher in neonatal PLTs (Wilcoxon p=0.026), indicating less membrane fluidity.

 

Conclusion: Together, these findings demonstrate that neonatal and adult PLTs have distinct lipidomic profiles that may contribute to differences in PLT activation and inflammatory signaling. How these differences contribute to the harm seen with neonatal PLT transfusion is an area of active research.

 

 

 

Kimberley Banfield, MBBS: No relevant conflicts of interest to declare.